That is, we found that patients with a tumor microenvironment (TME) rich in CD163+Foxp3+ CD80+ experience a higher rate of cancer recurrence compared to patients with TME low in CD163+Foxp3+ CD80+ [4]. This evidence concerns the gene FOXP3 and neoplasm.